Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (COVID-19), came as a significant health care challenge for humans in 2019-20. Based on recent laboratory and epidemiological studies, a growing list of mutations in the virus has the potential to enhance its transmission or help it evade the immune response. To further compound the problems, there are considerable challenges to the availability of effective, affordable, safe vaccines on a mass scale. These impediments have led some to explore additional options available in traditional medicines, especially immune-boosting natural products. Saffron has been used for centuries to treat fever, bronchitis, cold and other immune, respiratory disorders. Herein, we discuss the potential role of saffron during and after COVID-19 infection, focusing on immunomodulation, respiratory, renal, and cardiovascular functions. As a nutraceutical or drug supplement, it can alleviate the magnitude of COVID-19 symptoms in patients. The anti-inflammatory, antioxidant, and other medicinal properties attributed to saffron bioactive compounds can help in both pre-and post-infection management strategies. The abnormalities associated with COVID-19 survivors include anxiety, depression, sleep disturbances, and post-traumatic stress disorder. Saffron can help manage these post-hospitalization abnormalities (sub-acute and chronic) too, owing to its anti-depressant property. It can help common people boost immunity and manage depression, stress and anxiety caused due to prolonged lockdown, isolation or quarantine.

Structural, thermal and rheological properties of starches isolated from Indian quinoa varieties.

In this study starches isolated from Indian quinoa varieties were examined for physicochemical, morphological, thermal and rheological properties. Among isolated starches V1 showed higher starch yield and lower purity (48.45% and 98.32%) than V2 (41.28 and 98.53%). The amylose content was higher for V1 (12.10%) than V2 (9.46%). Swelling powers and solubility of the starches increased with increasing temperature. Peak viscosity (386.4 RVU) was higher for V1. In contrast V2 showed higher pasting temperature (72.85°C). Low setback viscosity of the starches suggests that they can be profitably used in frozen and refrigerated foods. Starch granules from both varieties were irregular, angular and polygonal in shape. The starch granule size obtained by SEM was 1.23µm for V1 and 1.19µm for V2. Both starches showed a typical A-type diffractrometric pattern with varying crystallinity. Further V1 showed lower transition temperatures (To, Tp and Tc) than V2. FTIR spectroscopy showed higher intensity and broader shape of V2 at OH stretch which can be due to its higher crystallinity. Increased interest is shown in quinoa starch because of its unique microcrystalline granules. Higher yield and purity values suggest that both varieties can be exploited for commercial starch utilization.